Literature DB >> 8567044

Pathophysiological consequences of changes in the coupling ratio of Na,K-ATPase for renal sodium reabsorption and its implications for hypertension.

D E Orosz1, U Hopfer.   

Abstract

Recent reports indicate that alpha 1-Na,K-ATPase from Dahl salt-sensitive (DS) rats contains a glutamine for leucine substitution associated with increased Na-K coupling at unchanged maximal velocity. Genetic analyses suggest that alpha 1-Na,K-ATPase is a potential hypertension gene. Therefore, we investigated whether renal Na+ metabolism could constitute a pathophysiological link between the molecular/functional change in Na,K-ATPase and hypertension. We simulated the consequences of increased Na-K coupling on overall Na-bicarbonate reabsorption in a proximal tubular transport model that incorporates apical Na-H exchanger and basolateral Na-bicarbonate cotransporter, K+ channel, and Na,K-ATPase. As expected, increases in the levels of the former three transport pathways yielded higher Na+ reabsorption. In contrast, increases in the maximal velocity of the Na,K-ATPase with a normal 3:2 (Na-K) coupling ratio did not increase Na+ reabsorption when apical Na-H exchange activity was limiting overall absorption. However, an increase in the Na-K coupling from 3:2 to 3:1, reported for the mutant alpha 1-Na,K-ATPase in DS rats, was associated with greater Na+ reabsorption. This increase is a consequence of lower cytosolic pH and secondary stimulation of the Na-H exchanger at its allosteric H+ site. Decreased pH results from activation of Na-bicarbonate cotransport by Na,K-ATPase-dependent membrane hyperpolarization due to greater charge movement in 3:1 Na-K coupling. Thus, an increase in the Na-K coupling ratio results in an altered set point for cellular Na+ metabolism, with higher sodium reabsorption at unchanged Na,K-ATPase levels. The simulations thereby lend support for a unifying explanation for the salt sensitivity of DS rats, which has been proposed to stem from a mutation in the alpha 1-Na,K-ATPase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8567044     DOI: 10.1161/01.hyp.27.2.219

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

Review 1.  Endogenous cardiotonic steroids and salt-sensitive hypertension.

Authors:  Olga V Fedorova; Joseph I Shapiro; Alexei Y Bagrov
Journal:  Biochim Biophys Acta       Date:  2010-03-27

2.  The alpha1 Na,K-ATPase gene is a susceptibility hypertension gene in the Dahl salt-sensitiveHSD rat.

Authors:  V L Herrera; H X Xie; L V Lopez; N J Schork; N Ruiz-Opazo
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

3.  Plasma level of the endogenous sodium pump ligand marinobufagenin is related to the salt-sensitivity in men.

Authors:  Olga V Fedorova; Edward G Lakatta; Alexei Y Bagrov; Olle Melander
Journal:  J Hypertens       Date:  2015-03       Impact factor: 4.844

4.  Effect of Cardiotonic Steroid Marinobufagenin on Vascular Remodeling and Cognitive Impairment in Young Dahl-S Rats.

Authors:  Yulia N Grigorova; Ondrej Juhasz; Jeffrey M Long; Valentina I Zernetkina; Mikayla L Hall; Wen Wei; Christopher H Morrell; Natalia Petrashevskaya; Audrey Morrow; Katherine H LaNasa; Alexei Y Bagrov; Peter R Rapp; Edward G Lakatta; Olga V Fedorova
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

5.  Leptin and the Regulation of Renal Sodium Handling and Renal Na-Transporting ATPases: Role in the Pathogenesis of Arterial Hypertension.

Authors:  Jerzy Bełtowski
Journal:  Curr Cardiol Rev       Date:  2010-02

6.  Growth, immortalization, and differentiation potential of normal adult human proximal tubule cells.

Authors:  David E Orosz; Philip G Woost; Robert J Kolb; Margaret B Finesilver; Wenwu Jin; Phyllis S Frisa; Chee-Keong Choo; Chung-Fai Yau; Kwok-Wah Chan; Martin I Resnick; Janice G Douglas; John C Edwards; James W Jacobberger; Ulrich Hopfer
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Jan-Feb       Impact factor: 2.416

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.